Article Versions Notes

Varga T, Szilvásy N, Schelz Z, Kanizsainé Minorics R, Veres K, Temesszentandrási-Ambrus C, Tátrai P, Hohmann J, Gáborik Z, Kis E. Ginger and Its Purified Major Components Inhibit Clinically Relevant Uptake and Efflux Transporters In Vitro. Pharmaceutics. 2026; 18(2):149. https://doi.org/10.3390/pharmaceutics18020149

Varga, Tamás, Nóra Szilvásy, Zsuzsanna Schelz, Renáta Kanizsainé Minorics, Katalin Veres, Csilla Temesszentandrási-Ambrus, Péter Tátrai, Judit Hohmann, Zsuzsanna Gáborik, and Emese Kis. 2026. "Ginger and Its Purified Major Components Inhibit Clinically Relevant Uptake and Efflux Transporters In Vitro" Pharmaceutics 18, no. 2: 149. https://doi.org/10.3390/pharmaceutics18020149

Varga, T., Szilvásy, N., Schelz, Z., Kanizsainé Minorics, R., Veres, K., Temesszentandrási-Ambrus, C., Tátrai, P., Hohmann, J., Gáborik, Z., & Kis, E. (2026). Ginger and Its Purified Major Components Inhibit Clinically Relevant Uptake and Efflux Transporters In Vitro. Pharmaceutics, 18(2), 149. https://doi.org/10.3390/pharmaceutics18020149